2024
Targeted intracellular delivery of dimeric STINGa by two pHLIP peptides for treatment of solid tumors
Moshnikova A, DuPont M, Iraca M, Klumpp C, Visca H, Allababidi D, Pelzer P, Engelman D, Andreev O, Reshetnyak Y. Targeted intracellular delivery of dimeric STINGa by two pHLIP peptides for treatment of solid tumors. Frontiers In Pharmacology 2024, 15: 1346756. PMID: 38495104, PMCID: PMC10940318, DOI: 10.3389/fphar.2024.1346756.Peer-Reviewed Original ResearchTargeted intracellular deliveryIntracellular deliveryTreatment of solid tumorsAnti-cancer immunityPHLIP peptideBinding to plasma proteinsBlood half-lifeTumor eradicationSolid tumorsCytokine activityTumorTargeted deliveryDelivery approachesHalf-lifePlasma proteinsDMSAPHLIPDeliveryMembrane lipid bilayerPeptide
2022
Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP
Moshnikova A, DuPont M, Visca H, Engelman D, Andreev O, Reshetnyak Y. Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP. Frontiers In Oncology 2022, 12: 1023959. PMID: 36330464, PMCID: PMC9622777, DOI: 10.3389/fonc.2022.1023959.Peer-Reviewed Original ResearchTumor-associated macrophagesCancer-associated fibroblastsSTING agonistsT cellsTumor microenvironmentDendritic cellsCT26 tumorsM2-type tumor-associated macrophagesAnti-cancer immunityTumor-free miceEradication of tumorsActivation of cytokinesNovel STING agonistSuppressor cellsSingle doseImmune cellsIntratumoral hemorrhageTherapeutic effectTumor stromaImmune memoryNude miceAdditional injectionTumorsCancer cellsMice